NASDAQ$LQDA
Liquidia Corporation · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Reported financial results for the second quarter ended June 30, 2024.
Liquidia Corporation reported revenue of $3.7 million and a net loss of $27.9 million for the second quarter ended June 30, 2024. The company's cash and cash equivalents totaled $133.1 million as of June 30, 2024.
- Judge Andrews denied the motion for preliminary injunction filed by United Therapeutics (UTHR) in its lawsuit alleging that YUTREPIA infringes U.S. Patent No. 11,826,327 (‘327 patent).
- The U.S. District Court for the District of Columbia has denied motions for a temporary restraining order and preliminary injunction requested by UTHR in its suit against the U.S. Food and Drug Administration (FDA).
- Liquidia presented two live thematic poster sessions and five encore presentations covering the company’s investigational products, YUTREPIA™ (treprostinil) inhalation powder and L606 (liposomal treprostinil) inhalation suspension at the World Symposia on Pulmonary Hypertension.
- Liquidia presented data related to the investigational use of L606 (liposomal treprostinil) inhalation suspension in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) at the ATS Conference in San Diego.
Headline financials
Revenue & EPS history
Liquidia · Revenue · Quarterly
$3.66M
Revenue by segment
Liquidia · $3.7M total across 1 segment · Q3 2023
- Promotion Agreement$3.7M+15.6%100.0%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2024
+3.4%
Avg return
Earnings day
+5.4%
Avg return
5 days after
+1.7%
Avg return
30 days after
60%
18 / 30 earnings
Positive
+31.8%
Q2 2022
Best reaction
-13.3%
Q2 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +25.4% | +34.5% | — | |
| Q4 2025 | +0.4% | +12.9% | +9.6% | |
| Q3 2025 | +8.8% | +7.1% | +38.5% | |
| Q1 2025 | -1.0% | +3.0% | +16.8% | |
| Q4 2024 | +1.2% | +6.2% | -6.9% | |
| Q3 2024 | -5.6% | -7.6% | +2.7% | |
| Q2 2024 | +2.9% | +10.4% | -17.7% | |
| Q1 2024 | -0.8% | +5.4% | +10.4% | |
| Q4 2023 | +9.6% | +11.3% | -0.2% | |
| Q3 2023 | -1.0% | -4.4% | +9.8% | |
| Q2 2023 | -6.3% | -8.9% | -7.5% | |
| Q1 2023 | +5.0% | +7.8% | +26.1% | |
| Q4 2022 | +13.5% | +13.2% | +6.3% | |
| Q3 2022 | +0.8% | -0.4% | +14.6% | |
| Q2 2022 | +31.8% | +34.5% | +9.9% | |
| Q1 2022 | +7.7% | +21.9% | -17.0% | |
| Q4 2021 | +11.2% | +9.7% | -17.8% | |
| Q3 2021 | +9.9% | +9.7% | +3.1% | |
| Q2 2021 | -0.8% | +11.8% | +16.4% | |
| Q1 2021 | -0.7% | +0.0% | -0.7% | |
| Q4 2020 | -7.4% | -6.6% | +2.2% | |
| Q3 2020 | +0.7% | -12.7% | -36.9% | |
| Q2 2020 | -13.3% | -8.5% | -23.3% | |
| Q1 2020 | +8.0% | +8.7% | +13.4% | |
| Q4 2019 | -1.5% | +1.7% | +54.5% | |
| Q3 2019 | +5.2% | +0.6% | +6.4% | |
| Q2 2019 | +6.4% | -0.7% | -40.6% | |
| Q1 2019 | -3.0% | -0.4% | +2.6% | |
| Q4 2018 | +3.0% | +3.1% | -43.8% | |
| Q3 2018 | -9.2% | -1.3% | +19.4% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro